FDA To Review Approval Of Norvasc Generic As 505 (b) (2) Gateway Is Tested In Court

Law360, New York (February 9, 2004, 12:00 AM EST) -- In a move that could have broad ramifications for 505 (b) (2) generic drug approvals, the U.S. Food and Drug Administration has stayed its decision to allow Indian drug maker Dr. Reddy's Laboratories to market a generic version of Pfizer’s anti-hypertension drug Norvasc.

The FDA made the decision pending a court verdict following hearings last July in which Pfizer challenged Dr. Reddy's right to market the drug. The FDA’s letter indicated the re-evaluation was prompted by questions raised about the source of the data relied on...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.